hepatitis C
European Commission approves first drug for hepatitis D
August 6, 2020Business Services EC, hepatitis C, hepatitis D
The European Commission has approved Heplcudex (bulvirtide) as the first hepatitis D drug. It was jointly developed by researchers at …
AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients
September 27, 2019Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma
The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …
FDA warns three Hepatitis C drugs may worsen liver function in some rare cases
August 29, 2019Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health
The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …
FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)
May 1, 2019Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma
The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …
Reformulated OxyContin led to spike in Hepatitis C infections
February 5, 2019Manufacturing and Production OxyContin, USA, hepatitis C, heroin, infectious diseases, opioids
Efforts to create an “abuse deterrent” OxyContin pill inadvertently led to an increase in the number of Hepatitis C infections, …
AbbVie’s case against the NHS thrown out of court
January 22, 2019Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health
A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …
Gilead to release generic versions of hep C meds over a decade before patent expiry
September 28, 2018Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma
Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …
US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute
April 26, 2018Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi
MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …
Top Ten most popular articles on Pharmafile.com this week
April 13, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten
It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …
New hepatitis C combo boasts 97% cure rate for just $300
April 12, 2018Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi
A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …
Gilead launches hep C drug Sovaldi in China at one-fifth of US price
November 29, 2017Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi
Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …
MSD pulls out of hep C space to Gilead’s relief
October 2, 2017Sales and Marketing MSD, biotech, drugs, hepatitis C, pharma, pharmaceutical
MSD, known as Merck in North America, has announced that it will curtail its attempts to make an impact in …
J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion’s stock
September 12, 2017Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, achillion, hepatitis C, pharma
Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to …
Nine in 10 people unaware they have hepatitis
July 28, 2017Medical Communications, Research and Development Gilead, biotech, drugs, hepatitis, hepatitis C, pharma, pharmaceutical
The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with …
Regulus CEO heads to exit as company struggles with FDA hold
May 5, 2017Medical Communications, Research and Development Regulus, hepatitis C
Regulus seemed to be in a good place just last year as its lead drug candidate performed well in a …
Latest content
FibroFind appoints Lee Borthwick as CEO
